This activity expired on May 8, 2025; credit is no longer available.

Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education

Media: Enduring Material
Activity Release Date: May 9, 2024
Activity Expiration Date: May 8, 2025
Time to Complete Activity: 60 minutes

Activity Description

Despite the remarkable advances made with targeted therapies and immunotherapies, chemotherapy remains the primary treatment option for many patients with metastatic TNBC and HR+, HER2- breast cancer. Reliance on chemotherapy puts these patients at risk of experiencing poor outcomes and a diminished quality of life, highlighting a pressing need for new treatment approaches. One source of hope comes in the form of antibody-drug conjugates (ADCs), a class of drug combining a highly selective antibody with a potent cytotoxic agent. Sacituzumab govitecan (SG), a TROP2-targeting ADC, has received regulatory approvals for TNBC and HR+, HER2- breast cancer. These approvals, coupled with encouraging clinical evidence from ongoing investigations, herald a new era of therapy, bringing hope to patients with limited treatment options and unmet needs.

This PeerView educational activity, developed in partnership with Guiding Researchers and Advocates to Scientific Partnerships (GRASP) and The Chrysalis Initiative, provides multidisciplinary professionals with the latest clinical data on the role of TROP2-targeting ADCs in breast cancer and guidance on the optimal utilization of TROP2-targeting ADCs in TNBC and HR+, HER2- breast cancer in the context of current evidence and expert recommendations. It aims to provide guidance on best practices for adverse event management and patient education.

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, physician assistants, nurses, nurse navigators, patients/caregivers, and other healthcare professionals involved in the care of patients with TNBC and HR+, HER2-breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the efficacy and safety profiles and current clinical roles of TROP-targeting ADCs in TNBC and HR+, HER2- MBC
• Mitigate adverse events associated with different TROP2-targeting ADCs in TNBC and HR+, HER2- MBC
• Apply best practices for patient education and provision of team-based, patient-centric, equitable care to all patients with TNBC and HR+, HER2- MBC, including those in underserved communities

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota

Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Curio Science.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and The Chrysalis Initiative. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.0 point: Care Continuum, Coordination of Care, Diagnosis and Staging, Nursing Practice, Oncologic Emergencies, Oncology Nursing Practice, Psychosocial Dimension of Care, Symptom Management, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 5/8/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD/ILNA/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on May 8, 2025; credit is no longer available.

Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education

Media: Enduring Material
Activity Release Date: May 9, 2024
Activity Expiration Date: May 8, 2025
Time to Complete Activity: 60 minutes

Activity Description

Despite the remarkable advances made with targeted therapies and immunotherapies, chemotherapy remains the primary treatment option for many patients with metastatic TNBC and HR+, HER2- breast cancer. Reliance on chemotherapy puts these patients at risk of experiencing poor outcomes and a diminished quality of life, highlighting a pressing need for new treatment approaches. One source of hope comes in the form of antibody-drug conjugates (ADCs), a class of drug combining a highly selective antibody with a potent cytotoxic agent. Sacituzumab govitecan (SG), a TROP2-targeting ADC, has received regulatory approvals for TNBC and HR+, HER2- breast cancer. These approvals, coupled with encouraging clinical evidence from ongoing investigations, herald a new era of therapy, bringing hope to patients with limited treatment options and unmet needs.

This PeerView educational activity, developed in partnership with Guiding Researchers and Advocates to Scientific Partnerships (GRASP) and The Chrysalis Initiative, provides multidisciplinary professionals with the latest clinical data on the role of TROP2-targeting ADCs in breast cancer and guidance on the optimal utilization of TROP2-targeting ADCs in TNBC and HR+, HER2- breast cancer in the context of current evidence and expert recommendations. It aims to provide guidance on best practices for adverse event management and patient education.

Target Audience

This activity has been designed to meet the educational needs of nurse practitioners, physician assistants, nurses, nurse navigators, patients/caregivers, and other healthcare professionals involved in the care of patients with TNBC and HR+, HER2-breast cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the efficacy and safety profiles and current clinical roles of TROP-targeting ADCs in TNBC and HR+, HER2- MBC
• Mitigate adverse events associated with different TROP2-targeting ADCs in TNBC and HR+, HER2- MBC
• Apply best practices for patient education and provision of team-based, patient-centric, equitable care to all patients with TNBC and HR+, HER2- MBC, including those in underserved communities

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jamie Carroll, APRN, CNP, MSN
Assistant Professor of Oncology
Nurse Practitioner
Mayo Clinic
Rochester, Minnesota

Jamie Carroll, APRN, CNP, MSN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Sermonix Pharmaceuticals; and Talzenna.
Speakers Bureau participant with Curio Science.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and The Chrysalis Initiative. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:
1.0 point: Care Continuum, Coordination of Care, Diagnosis and Staging, Nursing Practice, Oncologic Emergencies, Oncology Nursing Practice, Psychosocial Dimension of Care, Symptom Management, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 5/8/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This NCPD/ILNA/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on May 24, 2025; credit is no longer available.

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care

Media: Enduring Material

Activity Release Date: April 25, 2024

Activity Expiration Date: May 24, 2025

Time to Complete Activity: 90 minutes

Activity Description

The treatment landscape for lung cancer has undergone a remarkable transformation in recent years, primarily due to the advent of immune checkpoint inhibitors (ICIs). These ground-breaking therapies have shown significant improvements in overall survival and durable responses in locally advanced and metastatic NSCLC without genomic alterations. More recently, the benefits of ICIs have extended to early-stage, resectable disease settings, offering the potential for cure and reduced recurrence rates. Ongoing intensive research continues to refine the role and application of current ICIs, and other novel approaches are being investigated as well, promising even more progress in the future.

This PeerView educational activity, based on a recent live symposium, incorporates the latest data and guideline recommendations, expert discussions, and illustrative cases to provide comprehensive guidance on the use of current and emerging immunotherapies throughout the NSCLC disease continuum. In addition, the expert panel explains best practices for recognizing, diagnosing, and managing immune-related adverse events (irAEs) associated with ICI-based therapies, as well as strategies to improve communication and education to individualize care.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other multidisciplinary and interprofessional team members involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Examine the latest evidence supporting the use of current and emerging ICIs and their combinations in the treatment of NSCLC
• Integrate ICI-based regimens into individualized treatment plans for eligible patients with NSCLC through effective team-based collaboration
• Implement best practices for diagnosing and managing irAEs in patients with NSCLC receiving treatment with ICIs and combinations
• Provide education, guidance, and support to patients with NSCLC and their caregivers to make informed decisions and optimize outcomes during treatment and survivorship

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager Care Signature, Oncology

Oncology Nurse Practitioner

Yale Comprehensive Cancer Center & Smilow Cancer Center

Associate Professor

Yale School of Nursing

New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner

Abramson Cancer Center

University of Pennsylvania

Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.

Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.

Faculty/Planner

Matthew A. Gubens, MD, MS, FASCO

Professor of Medicine

Medical Director, Thoracic Medical Oncology

Division of Hematology/Oncology

Department of Medicine

University of California San Francisco

San Francisco, California

Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; Johnson & Johnson; Merus; Sanofi; and Summit Therapeutics Inc.

Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell (all paid to institution).

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca, Bristol Myers Squibb, and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:

1.5 points: Care Continuum, Nursing Practice, Professional Practice/Performance, Psychosocial Dimension of Care, Roles of the APRN, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on May 24, 2025; credit is no longer available.

Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care

Media: Enduring Material

Activity Release Date: April 25, 2024

Activity Expiration Date: May 24, 2025

Time to Complete Activity: 90 minutes

Activity Description

The treatment landscape for lung cancer has undergone a remarkable transformation in recent years, primarily due to the advent of immune checkpoint inhibitors (ICIs). These ground-breaking therapies have shown significant improvements in overall survival and durable responses in locally advanced and metastatic NSCLC without genomic alterations. More recently, the benefits of ICIs have extended to early-stage, resectable disease settings, offering the potential for cure and reduced recurrence rates. Ongoing intensive research continues to refine the role and application of current ICIs, and other novel approaches are being investigated as well, promising even more progress in the future.

This PeerView educational activity, based on a recent live symposium, incorporates the latest data and guideline recommendations, expert discussions, and illustrative cases to provide comprehensive guidance on the use of current and emerging immunotherapies throughout the NSCLC disease continuum. In addition, the expert panel explains best practices for recognizing, diagnosing, and managing immune-related adverse events (irAEs) associated with ICI-based therapies, as well as strategies to improve communication and education to individualize care.

Target Audience

This activity has been designed to meet the educational needs of oncology nurses, nurse navigators, nurse practitioners, oncologists, and other multidisciplinary and interprofessional team members involved in the care of patients with NSCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Examine the latest evidence supporting the use of current and emerging ICIs and their combinations in the treatment of NSCLC
• Integrate ICI-based regimens into individualized treatment plans for eligible patients with NSCLC through effective team-based collaboration
• Implement best practices for diagnosing and managing irAEs in patients with NSCLC receiving treatment with ICIs and combinations
• Provide education, guidance, and support to patients with NSCLC and their caregivers to make informed decisions and optimize outcomes during treatment and survivorship

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner

Marianne Davies, DNP, ACNP, AOCNP, FAAN

Program Manager Care Signature, Oncology

Oncology Nurse Practitioner

Yale Comprehensive Cancer Center & Smilow Cancer Center

Associate Professor

Yale School of Nursing

New Haven, Connecticut

Marianne Davies, DNP, ACNP, AOCNP, FAAN, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner

Beth Sandy, MSN, CRNP, FAPO

Thoracic Oncology Nurse Practitioner

Abramson Cancer Center

University of Pennsylvania

Philadelphia, Pennsylvania

Beth Sandy, MSN, CRNP, FAPO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc. and Janssen Pharmaceuticals, Inc.

Speakers Bureau participant with Amgen Inc.; AstraZeneca; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; and Takeda Pharmaceutical Company Limited.

Faculty/Planner

Matthew A. Gubens, MD, MS, FASCO

Professor of Medicine

Medical Director, Thoracic Medical Oncology

Division of Hematology/Oncology

Department of Medicine

University of California San Francisco

San Francisco, California

Matthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; Johnson & Johnson; Merus; Sanofi; and Summit Therapeutics Inc.

Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell (all paid to institution).

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca, Bristol Myers Squibb, and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points as follows:

1.5 points: Care Continuum, Nursing Practice, Professional Practice/Performance, Psychosocial Dimension of Care, Roles of the APRN, Symptom Management, Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can be claimed in each subject area domain. The total amount of points claimed may not exceed the total amount of nursing continuing professional development (NCPD) or CME awarded from this course and may only apply to the credential being renewed.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/ILNA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 16, 2025; credit is no longer available.

Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals

Media: Enduring Material
Activity Release Date: April 17, 2024
Activity Expiration Date: April 16, 2025
Time to Complete Activity: 45 minutes

Activity Description

Test your knowledge of lung cancer screening and early interventions in this question-based activity that adapts to your learning needs, featuring leading experts who review the evolving risk criteria and guideline recommendations and offer practical, evidence-based guidance for overcoming barriers and implementing current and emerging screening strategies for high-risk individuals.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, family practitioners, and other clinicians involved in the care of individuals at high risk of lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the evidence supporting lung cancer screening in clinical practice and the expanding screening eligibility criteria in lung cancer
• Implement current guideline recommendations (eg, USPSTF) for lung cancer screening and identification of patients who are considered to be high-risk and eligible for screening
• Apply current and emerging team-based strategies to improve lung cancer screening
• Describe advances in local and systemic therapies for resectable lung cancer that can improve outcomes in patients diagnosed early through lung cancer screening

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lecia V. Sequist, MD, MPH
Program Director
Cancer Early Detection & Diagnostics
Massachusetts General Hospital
The Landry Family Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Lecia V. Sequist, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Delfi Diagnostics; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Patrick Nana-Sinkam, MD, FCCP
Professor of Medicine
Chair, Division of Pulmonary Diseases and Critical Care Medicine
Linda Grandis Blatt Chair of Lung Cancer Research
Associate Director, Wright Center for Clinical and Translational Research
Virginia Commonwealth University
Richmond, Virginia

Patrick Nana-Sinkam, MD, FCCP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/16/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 16, 2025; credit is no longer available.

Screening and Early Intervention as the Keys to Success in Lung Cancer: A Practical Approach to Implementing Lung Cancer Screening for High-Risk Individuals

Media: Enduring Material
Activity Release Date: April 17, 2024
Activity Expiration Date: April 16, 2025
Time to Complete Activity: 45 minutes

Activity Description

Test your knowledge of lung cancer screening and early interventions in this question-based activity that adapts to your learning needs, featuring leading experts who review the evolving risk criteria and guideline recommendations and offer practical, evidence-based guidance for overcoming barriers and implementing current and emerging screening strategies for high-risk individuals.

Target Audience

This activity has been designed to meet the educational needs of pulmonologists, family practitioners, and other clinicians involved in the care of individuals at high risk of lung cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the evidence supporting lung cancer screening in clinical practice and the expanding screening eligibility criteria in lung cancer
• Implement current guideline recommendations (eg, USPSTF) for lung cancer screening and identification of patients who are considered to be high-risk and eligible for screening
• Apply current and emerging team-based strategies to improve lung cancer screening
• Describe advances in local and systemic therapies for resectable lung cancer that can improve outcomes in patients diagnosed early through lung cancer screening

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Lecia V. Sequist, MD, MPH
Program Director
Cancer Early Detection & Diagnostics
Massachusetts General Hospital
The Landry Family Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Lecia V. Sequist, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AstraZeneca; Delfi Diagnostics; and Novartis Pharmaceuticals Corporation.

Faculty/Planner
Patrick Nana-Sinkam, MD, FCCP
Professor of Medicine
Chair, Division of Pulmonary Diseases and Critical Care Medicine
Linda Grandis Blatt Chair of Lung Cancer Research
Associate Director, Wright Center for Clinical and Translational Research
Virginia Commonwealth University
Richmond, Virginia

Patrick Nana-Sinkam, MD, FCCP, has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and LUNGevity Foundation. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/16/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on May 2, 2025; credit is no longer available.

Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms

Media: Enduring Material
Activity Release Date: April 3, 2024
Activity Expiration Date: May 2, 2025
Time to Complete Activity: 60 minutes

Activity Description

The advent of innovative antibody platforms, including CD38 and BCMA-targeted strategies, has radically transformed modern management of multiple myeloma (MM), offering patients a broader spectrum of therapeutic choices along their treatment journey. For hematology-oncology pharmacists, the advent of innovative antibody platforms presents a clear opportunity to ensure effective care coordination, patient education, and the proper administration of highly effective treatment options.

In this recording from the 2024 Hematology/Oncology Pharmacy Association (HOPA) 20th Annual Conference, a panel of myeloma experts exchange ideas and present clinical cases to illustrate the central role that hematology-oncology pharmacists play in delivering care with antibody platforms in multiple myeloma. Each “Clinical Consult” case conversation will link to the latest evidence supporting CD38, BCMA, and non-BCMA antibody strategies and provide guidance on how pharmacists can lead the integration of innovative antibody platforms across the spectrum of myeloma care. Don’t miss this opportunity to learn from leading experts and sharpen your skills in the context of multiple myeloma care!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms, efficacy and safety evidence, and practice guidelines supporting the treatment roles of CD38, BCMA, and non-BCMA antibody platforms in MM
• Develop pharmacist-guided team protocols for the integration and safe administration of antibody platforms across the spectrum of MM
• Address practical aspects of team care when using antibody platforms, including potential drug interactions, dosing, safety, patient/staff counseling, and managing supportive therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Professor, Hematology/Medical Oncology and Pharmacology and Chemical Biology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; EMD Serono; ERASCA, INC.; Janssen Pharmaceuticals, Inc.; and Tubulis.
Grant/Research Support from ADC Therapeutics SA; Amgen; Bayer Corporation; Bristol Myers Squibb; GlaxoSmithKline; Hutchison Medipharma Ltd.; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences Inc.; Meryx Inc.; MorphoSys AG; Pfizer; Ranok Therapeutics Co. Ltd.; and Xencor, Inc. Research funding to institution.

Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center
Kansas City, Kansas

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals; Pfizer; and Sanofi.

Faculty/Planner
James Davis, PharmD, BCOP
MUSC Hollings Cancer Center
Clinical Pharmacy Specialist – Malignant Hematology
Assistant Professor – MUSC College of Pharmacy
Charleston, South Carolina

James Davis, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Speaker for Janssen Pharmaceuticals, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-017-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on May 2, 2025; credit is no longer available.

Prescriptions for Successful Myeloma Care: Pharmacy Strategies for Delivering Effective Therapy With Antibody Platforms

Media: Enduring Material
Activity Release Date: April 3, 2024
Activity Expiration Date: May 2, 2025
Time to Complete Activity: 60 minutes

Activity Description

The advent of innovative antibody platforms, including CD38 and BCMA-targeted strategies, has radically transformed modern management of multiple myeloma (MM), offering patients a broader spectrum of therapeutic choices along their treatment journey. For hematology-oncology pharmacists, the advent of innovative antibody platforms presents a clear opportunity to ensure effective care coordination, patient education, and the proper administration of highly effective treatment options.

In this recording from the 2024 Hematology/Oncology Pharmacy Association (HOPA) 20th Annual Conference, a panel of myeloma experts exchange ideas and present clinical cases to illustrate the central role that hematology-oncology pharmacists play in delivering care with antibody platforms in multiple myeloma. Each “Clinical Consult” case conversation will link to the latest evidence supporting CD38, BCMA, and non-BCMA antibody strategies and provide guidance on how pharmacists can lead the integration of innovative antibody platforms across the spectrum of myeloma care. Don’t miss this opportunity to learn from leading experts and sharpen your skills in the context of multiple myeloma care!

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology pharmacists, pharmacy managers, and other healthcare professionals involved in the management of multiple myeloma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Describe the mechanisms, efficacy and safety evidence, and practice guidelines supporting the treatment roles of CD38, BCMA, and non-BCMA antibody platforms in MM
• Develop pharmacist-guided team protocols for the integration and safe administration of antibody platforms across the spectrum of MM
• Address practical aspects of team care when using antibody platforms, including potential drug interactions, dosing, safety, patient/staff counseling, and managing supportive therapies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO
Professor, Hematology/Medical Oncology and Pharmacology and Chemical Biology
Emory University School of Medicine
Director, Phase I Clinical Trials Section
Winship Cancer Institute of Emory University
Atlanta, Georgia

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen; EMD Serono; ERASCA, INC.; Janssen Pharmaceuticals, Inc.; and Tubulis.
Grant/Research Support from ADC Therapeutics SA; Amgen; Bayer Corporation; Bristol Myers Squibb; GlaxoSmithKline; Hutchison Medipharma Ltd.; Janssen Pharmaceuticals, Inc.; Kezar Life Sciences Inc.; Meryx Inc.; MorphoSys AG; Pfizer; Ranok Therapeutics Co. Ltd.; and Xencor, Inc. Research funding to institution.

Co-Chair/Planner
Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Clinical Pharmacy Manager
Division of Hematologic Malignancies and Cellular Therapeutics
The University of Kansas Cancer Center
Kansas City, Kansas

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals; Pfizer; and Sanofi.

Faculty/Planner
James Davis, PharmD, BCOP
MUSC Hollings Cancer Center
Clinical Pharmacy Specialist – Malignant Hematology
Assistant Professor – MUSC College of Pharmacy
Charleston, South Carolina

James Davis, PharmD, BCOP, has a financial interest/relationship or affiliation in the form of:
Speaker for Janssen Pharmaceuticals, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Regeneron Pharmaceuticals, Inc., and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-24-017-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 21, 2025; credit is no longer available.

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Activity Description and Educational Objectives

Are you prepared to learn about BCMA strategies that will help you accelerate the achievement of deep and durable remissions in multiple myeloma (MM)? New evidence is pointing to the use of chimeric antigen receptor T-cell (CAR-T) constructs for MM in earlier lines of therapy, which will have implications for sequencing with other BCMA options. At the same time, “off-the-shelf” BCMA antibodies are transforming treatment choices in pretreated disease, offering clinicians another tool to achieve deep remissions. This activity features expert exchanges based around real-world patient cases that illustrate the central role of BCMA bispecifics and CAR-T therapy throughout the MM therapeutic journey. Each case conversation is linked to a short overview of the evidence supporting the experts’ treatment choices. Don’t miss this opportunity to “accelerate remission” and learn how to apply new science on BCMA platforms!

Upon completion of this activity, participants should be better able to:

• Cite the safety and efficacy evidence supporting the use of established and emerging anti-BCMA platforms, including CAR-T and off-the-shelf antibody options, across several lines of therapy in MM
• Integrate evidence-informed anti-BCMA platforms into customized sequential treatment plans for MM, including in early relapse and more heavily pretreated disease
• Develop protocols to address practical aspects of anti-BCMA therapy, including planning for referral to specialized care, using appropriate bridging regimens, considering off-the-shelf antibody therapy, and understanding dosing and AE management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2024 - March 21, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Co-Chair & Presenter
Hans Lee, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Multiple Myeloma Clinical Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Support

This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 21, 2025; credit is no longer available.

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Activity Description and Educational Objectives

Are you prepared to learn about BCMA strategies that will help you accelerate the achievement of deep and durable remissions in multiple myeloma (MM)? New evidence is pointing to the use of chimeric antigen receptor T-cell (CAR-T) constructs for MM in earlier lines of therapy, which will have implications for sequencing with other BCMA options. At the same time, “off-the-shelf” BCMA antibodies are transforming treatment choices in pretreated disease, offering clinicians another tool to achieve deep remissions. This activity features expert exchanges based around real-world patient cases that illustrate the central role of BCMA bispecifics and CAR-T therapy throughout the MM therapeutic journey. Each case conversation is linked to a short overview of the evidence supporting the experts’ treatment choices. Don’t miss this opportunity to “accelerate remission” and learn how to apply new science on BCMA platforms!

Upon completion of this activity, participants should be better able to:

• Cite the safety and efficacy evidence supporting the use of established and emerging anti-BCMA platforms, including CAR-T and off-the-shelf antibody options, across several lines of therapy in MM
• Integrate evidence-informed anti-BCMA platforms into customized sequential treatment plans for MM, including in early relapse and more heavily pretreated disease
• Develop protocols to address practical aspects of anti-BCMA therapy, including planning for referral to specialized care, using appropriate bridging regimens, considering off-the-shelf antibody therapy, and understanding dosing and AE management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2024 - March 21, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Co-Chair & Presenter
Hans Lee, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Multiple Myeloma Clinical Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Support

This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 17, 2025; credit is no longer available.

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Media: Enduring Material

Activity Release Date: March 18, 2024

Activity Expiration Date: April 17, 2025

Time to Complete Activity: 75 minutes

Activity Description

Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings.

Join PeerView, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancers for a new expert-led video designed to bring learners the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events. Participate now and help redefine optimal care for your patients.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the care of patients with endometrial or ovarian cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the rationale and efficacy and safety evidence for immunotherapy regimens, antibody-drug conjugates, PARP inhibitors, and other innovative approaches for patients with endometrial or ovarian cancer
• Develop individualized therapeutic plans, including via clinical trial enrollment, utilizing the latest biomarker data and guideline-recommended treatment algorithms for eligible patients with endometrial or ovarian cancer
• Implement collaborative, team-based strategies to mitigate and manage treatment-related AEs for patients with endometrial or ovarian cancer receiving modern therapeutic approaches, including use of immunotherapy, antibody-drug conjugates, and PARP inhibitors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Floor J. Backes, MD

Professor

Fellowship Director

Director of Clinical Research

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

The Ohio State University College of Medicine

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio

Floor J. Backes, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; BioNTech SE.; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Myriad Genetics, Inc.

Grant/Research Support from AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Natera, Inc.

Speaker for The GOG Foundation Inc.

Faculty/Planner

Bhavana Pothuri, MD, MS

Professor, Departments of Ob/Gyn and Medicine, NYU Grossman School of Medicine

Medical Director, Clinical Trials Office (CTO), Laura and Isaac Perlmutter Cancer Center

Director, Gynecologic Oncology Clinical Trials

New York, New York

Director, Diversity and Health Equity for Clinical Trials, GOG Foundation

Associate Clinical Trials Advisor, Ovarian and Endometrial Cancer, GOG Partners

Bhavana Pothuri, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Celsion Corporation/Immune Pharmaceuticals Inc.; I-MAB Biopharma Co., Ltd; InxMed; Merck & Co., Inc.; Mersana Therapeutics; Nuvation Bio, Inc.; Onconova Therapeutics; Sutro Biopharma, Inc.; Tesaro, Inc./GlaxoSmithKline; The GOG Foundation Inc; and Toray Group.

Grant/Research Support from Acrivon Therapeutics; Agenus Inc.; AstraZeneca; Celgene Corporation; Celsion Corporation/Immune Pharmaceuticals Inc.; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; Incyte; InxMed; Karyopharm Therapeutics; Merck & Co., Inc.; Novocure GmbH; NRG Oncology; Onconova Therapeutics; Seagen Inc.; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Toray Group; VBL Therapeutics; and Xencor.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 4/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 17, 2025; credit is no longer available.

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Media: Enduring Material

Activity Release Date: March 18, 2024

Activity Expiration Date: April 17, 2025

Time to Complete Activity: 75 minutes

Activity Description

Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings.

Join PeerView, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancers for a new expert-led video designed to bring learners the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events. Participate now and help redefine optimal care for your patients.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the care of patients with endometrial or ovarian cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the rationale and efficacy and safety evidence for immunotherapy regimens, antibody-drug conjugates, PARP inhibitors, and other innovative approaches for patients with endometrial or ovarian cancer
• Develop individualized therapeutic plans, including via clinical trial enrollment, utilizing the latest biomarker data and guideline-recommended treatment algorithms for eligible patients with endometrial or ovarian cancer
• Implement collaborative, team-based strategies to mitigate and manage treatment-related AEs for patients with endometrial or ovarian cancer receiving modern therapeutic approaches, including use of immunotherapy, antibody-drug conjugates, and PARP inhibitors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Floor J. Backes, MD

Professor

Fellowship Director

Director of Clinical Research

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

The Ohio State University College of Medicine

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio

Floor J. Backes, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; BioNTech SE.; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Myriad Genetics, Inc.

Grant/Research Support from AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Natera, Inc.

Speaker for The GOG Foundation Inc.

Faculty/Planner

Bhavana Pothuri, MD, MS

Professor, Departments of Ob/Gyn and Medicine, NYU Grossman School of Medicine

Medical Director, Clinical Trials Office (CTO), Laura and Isaac Perlmutter Cancer Center

Director, Gynecologic Oncology Clinical Trials

New York, New York

Director, Diversity and Health Equity for Clinical Trials, GOG Foundation

Associate Clinical Trials Advisor, Ovarian and Endometrial Cancer, GOG Partners

Bhavana Pothuri, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Celsion Corporation/Immune Pharmaceuticals Inc.; I-MAB Biopharma Co., Ltd; InxMed; Merck & Co., Inc.; Mersana Therapeutics; Nuvation Bio, Inc.; Onconova Therapeutics; Sutro Biopharma, Inc.; Tesaro, Inc./GlaxoSmithKline; The GOG Foundation Inc; and Toray Group.

Grant/Research Support from Acrivon Therapeutics; Agenus Inc.; AstraZeneca; Celgene Corporation; Celsion Corporation/Immune Pharmaceuticals Inc.; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; Incyte; InxMed; Karyopharm Therapeutics; Merck & Co., Inc.; Novocure GmbH; NRG Oncology; Onconova Therapeutics; Seagen Inc.; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Toray Group; VBL Therapeutics; and Xencor.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 4/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView